ClinicalTrials.gg
Not yet recruitingNCT07941167GEMS-PAFUpdated Nov 17, 2026

Gapless ECG-Monitoring for Stroke Prevention by Atrial Fibrillation Detection (GEMS-PAF-randomized Trial) - A Multi-centre, Randomized Controlled Outcome Trial.

An interventional study of Ultra-early Implantable loop recorder (ILR) implantation and Conventional stroke unit care ECG-monitoring in Ischaemic Stroke, TIA (Transient Ischemic Attack) and Atrial Fibrillation (Paroxysmal), sponsored by Medical University of Vienna. Not yet recruiting at 1 site in Austria. Open to participants aged 50 Years and older. Per ClinicalTrials.gov, last updated 2026-11-17.

Sponsored by Medical University of Vienna · Not applicable, Interventional, and Prevention

Updated Nov 17, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
442
Allocation
Randomized
Ages
50 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 49 studies in Ischemic Stroke with a site in Austria — 12 open to participants now, 15 under way, 1 of them phase 3. Ischemic Stroke · Austria.

Planned enrollment
19th of 34
442 · median 447
Started
2026
with 3 others
No phase
12 of 49
4 open now
Primary completion
2029-11
later than 12 of 14 live
Registered
49th of 49
by date

Among the 49 studies in Ischemic Stroke with a site in Austria, this one is the 19th largest by planned enrollment of the 34 interventional ones that give a count, is one of 4 that started in 2026, is one of 12 with no phase, reaches primary completion later than 12 of the 14 other live ones, and was the 49th registered.

Ischemic Stroke

2,619 studies on the registry are indexed under Ischemic Stroke; 978 are open to participants now.

Browse Ischemic Stroke studies →

Open to participants now

12 of the 49 studies in Ischemic Stroke with a site in Austria are open now. Recruiting first, the newest first:

6 more — sign in →

All 12 open studies →

A study can be open while its sites in Austria have not opened yet or have stopped. Only those recruiting at a site in Austria →

Who these studies take

Of the 662 Ischemic Stroke studies recruiting now, 396 (60%) set no upper age limit and 62 (9%) stop at 75 or younger; 26 take children under 18; 42 take healthy volunteers.

This study: 50 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 49 studies in Ischemic Stroke with a site in Austria, or all of them as a file.
02

Study summary

  1. What is the purpose of this clinical trial?

    All of the participants in this trial have been diagnosed with a stroke or transitoric ischaemic attack within 72 hours of inclusion. Strokes are usually caused by a blood clot, which subsequently leads to a blockage of a blood vessel in the brain. In more than 20% of patients who have had a stroke or a transient ischemic attack (TIA, a temporary reduction in blood flow to the brain), atrial fibrillation (AF) is detectable on the electrocardiogram (ECG) as a possible cause. AF is a cardiac arrhythmia characterized by irregular activity in the atria, affecting a total of 1-2% of the population. This means that approximately 100,000 people in Austria are affected. AF is also an age-related cardiac arrhythmia, so that its prevalence is already 6% among people over 65 and up to 20% among those over 80. The risk of a recurrent stroke is five times higher in patients with AF; however, this risk can be significantly reduced through the use of blood-thinning medications. However, many patients suffer from "silent" atrial fibrillation-which they themselves do not notice-that may go undetected using standard monitoring methods in the hospital or, later, on an outpatient basis. Standard monitoring methods consist of a resting electrocardiogram (ECG) upon admission to the hospital, the ECG recorded during the first few days of hospitalization in the stroke unit, and usually also a long-term ECG (Holter ECG monitoring, typically over 24 hours) performed as part of further inpatient treatment; the latter can be repeated on an outpatient basis after discharge. These measures can improve the detection rate of AF. One problem, however, is that time gaps arise between the individual monitoring steps, which means that a AF episode may go unnoticed. Since 2016, international treatment guidelines have also recommended extended, continuous ECG monitoring. One option available for this purpose is the implantable loop recorder (ILR), which is implanted under the skin and continuously records an ECG (loop = without interruption) for 3-5 years. The goal of this study is to investigate whether the early implantation of a loop recorder-already in the stroke unit-can detect atrial fibrillation to a greater extent than conventional, routine standard monitoring, and thereby prevent the occurrence of a recurrent stroke within one year. For this, it is necessary that 1) two groups be formed through random assignment and 2) a control magnetic resonance imaging (MRI) scan of the skull be performed after 12 months to detect even "silent" strokes.

  2. How does the clinical trial work, what is an implantable loop recorder, and how is it implanted?

The trial is being conducted at several hospitals in Austria. The departments leading the trial at the AKH are the Departments of Cardiology and Neurology. The aim of the study is to determine whether continuous ECG monitoring, initiated early-shortly after the stroke-can detect sudden-onset atrial fibrillation more frequently or earlier than a routine monitoring regimen used in everyday clinical practice. Half of all patients enrolled in the study will have a loop recorder implanted while they are still in the stroke unit, within the first 5 days after the stroke. The loop recorder is an established standard of care. This decision is made randomly (2 groups). The loop recorder is usually implanted on the left side of the chest during a minor surgical procedure. At this site, the doctor makes a small incision (approximately 1 cm long) under local anesthesia, through which the loop recorder is inserted directly under the skin. The incision is closed with sterile adhesive strips (rarely with a suture). A commercially available loop recorder from Abbott®, which has been used for this indication for several years, will be used-specifically, the "Assert-IQ" model. The loop recorder transmits events recorded daily to a network via the cellular network. Within this network, the physician can access patient data and take action as needed. The procedure typically takes only a few minutes and is minimally invasive. The loop recorder is used only for recording and documenting, not for treating cardiac arrhythmias. Once the wound has healed, malfunctions of the device are rare. However, external factors (e.g., electrical devices) can cause the loop recorder to malfunction.

More frequent detection of atrial fibrillation is expected as a result of more intensive ECG monitoring using an implantable loop recorder (ILR). In patients with AF following a stroke, oral anticoagulation with Marcumar or a related medication is associated with a significant reduction in the risk of recurrent strokes. We anticipate that, as a result, a larger proportion of patients will be treated with oral anticoagulants, which will in turn reduce the risk of recurrent strokes.

03

Conditions studied

  • Ischaemic Stroke
  • TIA (Transient Ischemic Attack)
  • Atrial Fibrillation (Paroxysmal)
  • Stroke Recurrence
  • Stroke Ischemic
  • Stroke (CVA) or TIA
  • Stroke (CVA) or Transient Ischemic Attack
  • Stroke (in Patients With Atrial Fibrillation)
  • Stroke Acute
  • Atrial Fibrillation (AF)
  • Atrial Fibrillation (Prevention of Stroke)
  • Cryptogenic Stroke

Keywords

  • Ischaemic Stroke
  • Gapless ECG monitoring
  • implantable loop recorder (ILR)
  • Stroke recurrence after 1 year
  • CHA2DS2-Vasc score
  • Stroke without prior atrial fibrillation (AF)
  • Atrial fibrillation (paroxysmal)
  • Atrial fibrillation
  • Ischaemic Stroke of known etiology
  • Cryptogenic Stroke
  • MRI
  • TIA
04

Who can participate

Ages eligible
50 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Any stroke/ without previously detected AF - if TIA: corresponding lesion on brain MRI/CT OR if no corresponding lesion on brain imaging: Speech disturbance or paresis at the index event AND duration of symptoms >10 minutes required
  • Age ≥ 50 and; for patients age 50-59 years at least one of the following risk factors: prior stroke/TIA to index stroke (includes covert/silent strokes on neuroimaging), diabetes, hypertension, current smoking, or heart failure
  • Index event (Stroke/TIA) within 72h
  • CHA2DS2-Vasc score >3
  • Written by the patient

Exclusion criteria

Exclusion Criteria:

  • Any history of AF/atypical flutter or any documented AF/atypical flutter prior to inclusion
  • Indication for oral anticoagulation at inclusion
  • Absolute for oral anticoagulation at inclusion
  • Implanted pacemaker device or cardioverter/defibrillator
  • Age below 50 years
  • \<1 year for reasons other than stroke
  • Pregnancy
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
442 participants (estimated)

Study arms

  • Experimental
    Group 1 - Gapless ECG-monitoring

    Gapless ECG-monitoring - implantation of an implantable loop recorder directly after ECG-monitoring during stroke unit admission.

    Device: Ultra-early Implantable loop recorder (ILR) implantation

  • Active comparator
    Group 2: Conventional stroke unit care by standard ECG-monitoring

    Conventional stroke unit care by standard ECG-monitoring throughout the first days after the index event (Stroke/TIA) and use of 24-72h-Holter ECG examination during hospital admission and/or after discharge in the ambulatory setting according to the post-stroke follow-up protocols of the treating stroke center.

    Other: Conventional stroke unit care ECG-monitoring

Interventions

  • DeviceUltra-early Implantable loop recorder (ILR) implantation

    The implantable loop recorder (ILR) that is going to be used is the Abbott Assert IQ of Abbott´s insertable cardiac monitor system (ICM) with remote monitoring. Implantation will occur during stroke unit stay, no more than 5 days after the index event (Stroke/TIA). ECG-monitoring is gapless. Assert IQ ICM is an insertable automatically activated and patient- activated monitoring system that records subcutaneous ECG and is indicated in the following cases: * Patients with clinical syndromes or situations at increased risk of cardiac arrhythmias * Patients who experience transient symptoms such as dizziness, palpitation, syncope, and chest pain that may suggest a cardiac arrhythmia Patients can use their smartphone to automatically transfer device data via a mobile App. Smart memory management eliminates the need for manual transmissions. The ILR will stay implanted until battery depletion or if the diagnosis and therapy will not demand any further prolonged monitoring.

  • OtherConventional stroke unit care ECG-monitoring

    Conventional stroke unit care ECG-monitoring includes continuous standard ECG-monitoring in the first days after the index event (Stroke/TIA). Additionally at least one 24-72h-Holter ECG will be performed during hospital admission and/or after discharge in the ambulatory setting according to the post-stroke follow-up protocols of the treating stroke center.

    Also known as: Holter-ECG

06

What researchers measure

Primary outcomes

  1. Stroke recurrence

    The primary outcome is the detection any recurrent ischemic stroke or TIA, systemic embolism and/or any covert cerebral infarction in the follow-up MRI performed after 12 months.

    Time frame: From enrollment to the final study concluding MRI a time period of 12 months is planned.

Secondary outcomes

  1. Time to first AF/ atrial flutter

    The time (days) from patient enrollment until the first detection of atrial fibrillation (AF)/ atrial flutter. Detection either by implantable loop recorder (Experimental group) or conventional stroke unit care ECG-monitoring protocols (Active comparator).

    Time frame: If no atrial fibrillation is detected, the time frame ends with the final study concluding MRI after a period of 12 months. If atrial fibrillation is detected, the time frame ends with the time of the first atrial fibrillation detection.

  2. AF burden

    With the help of the implantable loop recorder, the burden of atrial fibrillation episodes and the total amount of atrial fibrillation episodes can be recorded.

    Time frame: The time frame ends with the final study concluding MRI after a period of 12 months.

  3. Newly established oral anticoagulation

    The detection of atrial fibrillation, if appearing to be causally linked to the index event (Stroke/TIA), results in the establishment of an oral anticoagulation therapy. Therefore the rate of newly prescribed oral anticoagulation therapies among study participants, their starting date and any bleeding complications will be recorded.

    Time frame: The time frame ends with the final study concluding MRI after a period of 12 months.

  4. Cardioembolic events/Recurrent stroke/Myocardial infarction/Bleeding complication/Hospitalization

    Any fatal/non-fatal cardioembolic events, fatal/non-fatal recurrent stroke, fatal/non-fatal myocardial infarction, bleeding complications and hospitalizations at 12 months will be recorded.

    Time frame: The time frame ends with the final study concluding MRI after a period of 12 months.

  5. Death

    Any events leading to the death of the study participant will be recorded.

    Time frame: The time frame ends with the final study concluding MRI after a period of 12 months.

  6. Quality of life of study participants

    The quality of life of study participants will be estimated with the help of two scores. The National Institutes of Health Stroke Scale (NIHSS) and the Modified Rankin Scale (mRS).

    Time frame: The time frame ends with the final study concluding MRI after a period of 12 months.

07

Study locations

1 site
  • Medizinische Universität Wien, Allgemeines Krankenhaus der Stadt Wien (AKH)
    Vienna, State of Vienna 1090, Austria
08

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Undecided

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Nov 2026; primary completion for Nov 2029, 36 months later.

Of 573 non-industry interventional studies with no phase under Ischemic Stroke, half reached primary completion within 28 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 48. This study's planned 36 months is above that.

Counting every sponsor, half of 654 studies reached it within 27 months; a quarter within 14 and three quarters within 48.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 10, 2026
First posted
Nov 17, 2026
StartEst.
Nov 20, 2026
Primary completionEst.
Nov 20, 2029
CompletionEst.
Nov 20, 2029
Last update
Nov 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 17, 2026
Show all 1 update
  1. Nov 17, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07941167
Collaborators
Abbott, VASCage GmbH
Responsible party
Thomas Pezawas, MD (Assoc.-Prof. Priv.-Doz. Dr., Medical University of Vienna) — Principal investigator
First posted
Nov 17, 2026
Start date
Nov 20, 2026 (estimated)
Primary completion
Nov 20, 2029 (estimated)
Completion
Nov 20, 2029 (estimated)
Last update
Nov 17, 2026

Study contacts

Maximilian Serles, Dr. med. univ.
Contact
maximilian.serles@meduniwien.ac.at
+43 (0)1 40400-31350
Thomas Pezawas, Assoc.-Prof. Priv.-Doz. Dr.
principal investigator · Medizinische Universität Wien, Universitätsklinik für Innere Medizin II, Abteilung für Kardiologie
Stefan Greisenegger, Assoc. Prof. Priv. Doz Dr.
principal investigator · Medizinische Universität Wien, Universitätsklinik für Neurologie

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion